Provided by Tiger Fintech (Singapore) Pte. Ltd.

MediciNova

1.55
+0.08005.44%
Post-market: 1.550.00000.00%16:05 EDT
Volume:13.85K
Turnover:21.05K
Market Cap:76.02M
PE:-6.88
High:1.58
Open:1.51
Low:1.46
Close:1.47
Loading ...

MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042

THOMSON REUTERS
·
15 Nov 2024

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

GlobeNewswire
·
15 Nov 2024

MediciNova Inc reports results for the quarter - Earnings Summary

Reuters
·
14 Nov 2024

MediciNova: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

MediciNova notified of settlement in Sanofi Novartis litigation

TIPRANKS
·
12 Nov 2024

Medicinova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

THOMSON REUTERS
·
12 Nov 2024

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

GlobeNewswire
·
12 Nov 2024

MediciNova Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

MediciNova announces update of Phase 2/3 MN-166 trial at NEALS meeting

TIPRANKS
·
24 Oct 2024

Medicinova Announces Update of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS Patients (Combat-ALS) at the 2024 Annual Neals Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

THOMSON REUTERS
·
24 Oct 2024

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

GlobeNewswire
·
24 Oct 2024

MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago

Simply Wall St.
·
07 Oct 2024

BRIEF-Medicinova To Support NIH-funded Expanded Access Clinical Trial To Evaluate Ibudilast

Reuters
·
30 Sep 2024

Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

THOMSON REUTERS
·
30 Sep 2024

MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS

THOMSON REUTERS
·
30 Sep 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

GlobeNewswire
·
30 Sep 2024